POINT BIOPHARMA GLOBAL INC (PNT) Forecast, Price Target & Analyst Ratings
NASDAQ:PNT • US7305411099
12.5 USD
+0.02 (+0.16%)
At close: Dec 26, 2023
12.51 USD
+0.01 (+0.08%)
After Hours: 12/26/2023, 8:10:43 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for POINT BIOPHARMA GLOBAL INC (PNT).
Forecast Snapshot
Consensus Price Target
$15.05
+ 20.36% Upside
Next Earnings Forecast
Release DateMar 22, 2024
PeriodQ4 / 2023
EPS Estimate-$0.26
Revenue Estimate2.289M
ChartMill Buy Consensus
69.33%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$15.05
Upside
+ 20.36%
From current price of $12.50 to mean target of $15.05, Based on 15 analyst forecasts
Low
$12.63
Median
$12.75
High
$28.35
Price Target Revisions
1 Month
0.00%
3 Months
2.12%
Price Target Summary
15 analysts have analysed PNT and the average price target is 15.05 USD. This implies a price increase of 20.36% is expected in the next year compared to the current price of 12.5.
The average price target has been revised upward by 2.12% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
69.33%
PNT was analyzed by 15 analysts. The buy percentage consensus is at 69. So analysts seem to be have mildly positive about PNT.
In the previous month the buy percentage consensus was at a similar level.
PNT was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-12-21 | Brookline Capital | Downgrade | Buy -> Hold |
| 2023-10-24 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2023-10-06 | Raymond James | Downgrade | Outperform -> Market Perform |
| 2023-10-04 | JonesTrading | Downgrade | Buy -> Hold |
| 2023-10-04 | Truist Securities | Downgrade | Buy -> Hold |
| 2023-05-16 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2022-12-14 | Raymond James | Initiate | Outperform |
| 2022-11-30 | SVB Leerink | Initiate | Outperform |
| 2022-11-15 | Truist Securities | Maintains | Buy |
| 2022-10-11 | Oppenheimer | Initiate | Outperform |
| 2022-09-16 | Truist Securities | Initiate | Buy |
| 2022-09-14 | Berenberg | Initiate | Buy |
| 2022-09-07 | JonesTrading | Initiate | Buy |
| 2022-08-16 | Guggenheim | Initiate | Buy |
| 2022-07-06 | William Blair | Initiate | Outperform |
| 2022-05-26 | Jefferies | Upgrade | Hold -> Buy |
| 2021-12-17 | Mizuho | Initiate | Underperform |
| 2021-07-29 | Cowen & Co. | Initiate | Outperform |
| 2021-07-27 | Jefferies | Initiate | Hold |
| 2021-07-26 | Piper Sandler | Initiate | Overweight |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 22, 2024
PeriodQ4 / 2023
EPS Estimate-$0.26
Revenue Estimate2.289M
Revenue Q2Q-98.99%
EPS Q2Q1.39%
Number of Analysts12
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
83.86%
EPS (1 Month)
0.00%
EPS (3 Months)
14.94%
Next Earnings Summary
PNT is expected to report earnings on 3/22/2024. The consensus EPS estimate for the next earnings is -0.26 USD and the consensus revenue estimate is 2.29M USD.
The next earnings revenue estimate has been revised upward by 83.86% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 226.6M | 20.448M -90.98% | 35.182M 72.06% | 228.64M 549.88% | 146.86M -35.77% | 365.44M 148.84% | 649.09M 77.62% | 476.94M -26.52% | 569.65M 19.44% | |||
| EBITDA YoY % growth | N/A | N/A | 126.9M | -125.24M -198.69% | -142.41M -13.71% | 63.63M 144.68% | -138.37M -317.46% | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -13.1M | -45.5M -247.33% | 125.5M 375.82% | -120.451M -195.98% | -108.241M 10.14% | -15.595M 85.59% | -85.727M -449.70% | 54.341M 163.39% | 205.09M 277.41% | 145.62M -29.00% | 217.78M 49.55% | |
| Operating Margin | N/A | N/A | 55.38% | -589.06% | -307.66% | -6.82% | -58.37% | 14.87% | 31.60% | 30.53% | 38.23% | |
| EPS YoY % growth | N/A | N/A | N/A -52.78% | -0.89 9.21% | -1.04 -15.99% | 0.56 153.87% | -0.69 -223.67% | 0.80 215.25% | 1.87 134.50% | 1.55 -17.15% | 1.92 24.51% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.26 1.39% | -0.29 -81.80% | -0.30 -23.72% | -0.22 4.27% | -0.11 59.78% | -0.37 -28.47% | -0.37 -25.85% | -0.37 -69.72% | 2.08 2,080.77% | -0.35 5.41% | -0.33 10.81% | -0.31 16.22% |
| Revenue Q2Q % growth | 2.289M -98.99% | 1.136M -88.04% | 1.136M -76.82% | 13.13M 368.93% | 37.37M 1,532.59% | 295.93M 25,950.18% | 3.578M 214.96% | 3.578M -72.75% | 284.08M 660.18% | 2.562M -99.13% | 5.486M 53.33% | 10.67M 198.21% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -33.46M -117.48% | -33.498M -48.88% | -34.447M -9.35% | -22.077M 25.41% | 1.214M 103.63% | -33.154M 1.03% | -33.154M 3.75% | -34.164M -54.75% | -34.164M -2,914.19% | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
36.93%
EPS Next 5 Year
22.94%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
112.36%
Revenue Next 5 Year
72.58%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
38.92%
EBIT Next 5 Year
-10.32%
POINT BIOPHARMA GLOBAL INC / PNT Forecast FAQ
What is the average price target for POINT BIOPHARMA GLOBAL INC (PNT) stock?
15 analysts have analysed PNT and the average price target is 15.05 USD. This implies a price increase of 20.36% is expected in the next year compared to the current price of 12.5.
Can you provide the upcoming earnings date for POINT BIOPHARMA GLOBAL INC?
POINT BIOPHARMA GLOBAL INC (PNT) will report earnings on 2024-03-22, after the market close.
What are the consensus estimates for PNT stock next earnings?
The consensus EPS estimate for the next earnings of POINT BIOPHARMA GLOBAL INC (PNT) is -0.26 USD and the consensus revenue estimate is 2.29M USD.
How do analysts rate POINT BIOPHARMA GLOBAL INC (PNT)?
The consensus rating for POINT BIOPHARMA GLOBAL INC (PNT) is 69.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.